Trial Profile
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Primary biliary cirrhosis
- Focus Registrational; Therapeutic Use
- Acronyms POISE
- Sponsors Intercept Pharmaceuticals
- 14 Nov 2023 Results of sub analysis evaluating the impact of OCA on achievement of GGT, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 14 Nov 2023 Results of post hoc sub-analysis assessing the correlations of TE with fibrosis scoring systems, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 20 Sep 2022 According to an Intercept Pharmaceuticals Media Release, analysis comparing findings from the Phase 3 POISE trial and open-label extension to natural history data from the Global PBC and UK-PBC patient registries published in Gastroenterology.